Günter Henze

Pediatric Oncology Group — Canada

Medicine · Health Sciences

48h-index10.8kcitations232works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Lymphoblastic Leukemia research(97), Childhood Cancer Survivors' Quality of Life(44), Acute Myeloid Leukemia Research(41), Electrochemical Analysis and Applications(39), Analytical Chemistry and Sensors(21)

Publications232 total

A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALL
Cancers·2023· 3 citedOpen Access
Supplementary Figure Legend from Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
2023Open Access
Supplementary Tables 1 - 8 from Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
2023Open Access
Supplementary Figures 1 - 13 from Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
2023Open Access
Data from Expression of Late Cell Cycle Genes and an Increased Proliferative Capacity Characterize Very Early Relapse of Childhood Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figure Legend from Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
2023Open Access
Supplementary Methods from Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
2023Open Access
Supplementary Methods from Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
2023Open Access
Data from Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
2023Open Access
Supplementary Table 1 from Expression of Late Cell Cycle Genes and an Increased Proliferative Capacity Characterize Very Early Relapse of Childhood Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figure 1 from Expression of Late Cell Cycle Genes and an Increased Proliferative Capacity Characterize Very Early Relapse of Childhood Acute Lymphoblastic Leukemia
2023Open Access
Data from Expression of Late Cell Cycle Genes and an Increased Proliferative Capacity Characterize Very Early Relapse of Childhood Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Tables 1 - 8 from Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
2023Open Access
Supplementary Figure 2 from Expression of Late Cell Cycle Genes and an Increased Proliferative Capacity Characterize Very Early Relapse of Childhood Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figure 2 from Expression of Late Cell Cycle Genes and an Increased Proliferative Capacity Characterize Very Early Relapse of Childhood Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figures 1 - 13 from Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
2023Open Access
Supplementary Figure 1 from Expression of Late Cell Cycle Genes and an Increased Proliferative Capacity Characterize Very Early Relapse of Childhood Acute Lymphoblastic Leukemia
2023Open Access
Data from Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
2023Open Access
Supplementary Table 1 from Expression of Late Cell Cycle Genes and an Increased Proliferative Capacity Characterize Very Early Relapse of Childhood Acute Lymphoblastic Leukemia
2023Open Access
X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory <scp>ALL</scp>
EMBO Molecular Medicine·2022· 8 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Martin Schrappe(18), Arend von Stackelberg(14), Thomas Klingebiel(9), Alfred Reiter(8), Cornelia Eckert(8), Georg Mann(7), Wolfgang Ludwig(7), Bernhard Kremens(7), R. Hartmann(7), J. Ritter(6), Helmut Gadner(6), Karl Seeger(6), Anja Möricke(5), Martin Zimmermann(5), Charlotte M. Niemeyer(5), Hansjörg Riehm(5), Timm Denecke(5), Ingo G. Steffen(5), Daniel Misch(5), Christian Furth(5)